Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 18/20 | 1.00 |
| ▸ | CDK2 | P24941 | 18/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 18/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | LATS1 | O95835 | 1/20 | 0.76 |
| ▸ | PAK4 | O96013 | 1/20 | 0.76 |
| ▸ | RET | P07949 | 1/20 | 0.76 |
| ▸ | PIM1 | P11309 | 1/20 | 0.76 |
| ▸ | NQO2 | P16083 | 1/20 | 0.76 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.76 |
| ▸ | MARK3 | P27448 | 1/20 | 0.76 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.76 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.76 |
| ▸ | PRKCI | P41743 | 1/20 | 0.76 |
| ▸ | PSMC4 | P43686 | 1/20 | 0.76 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.76 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.76 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14543173 | 1.00 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11935124 | 0.87 | CHEK1 (0.81) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931197 | 0.87 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL10380123 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL2408669 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| Sch-900776 SCHEMBL17466881 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930861 | 0.86 | CHEK1 (0.80) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930942 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11930793 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 | |
| SCHEMBL11931195 | 0.86 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1RPS6KA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1942900-B1 | USE OF PYRAZOLO [1,5-A] PYRIMIDINE DERIVATIVES FOR INHIBITING KINASES METHODS FOR INHIBITING PROTEIN KINASES | MERCK SHARP & DOHME (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| US-8211854-B2 | Methods for inhibiting protein kinases | SCHERING CORPORATION (US) | 2012-07-03 | — | — | US | disclosed |
| EP-1931676-B1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORP (US) | 2011-11-16 | — | — | EP | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776865-B2 | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION | 2010-05-20 | — | — | US | disclosed |
| WO-2007044441-A2 | USE OF PYRAZOLO [1 , 5 -A] PYRIMIDINE DERIVATIVES FOR INHIBITING PROTEIN KINASES METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| WO-2007041712-A1 | PYRAZOLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
| US-20070083044-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CHEK1, CHEK2, BUB1 | CHEK1 1/4885CCNA2 675/4885CDK2 8/4885 |
| US-20100125068-A1 | METHODS FOR INHIBITING PROTEIN KINASES | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.